Concepedia

Temozolomide Plus Thalidomide in Patients With Advanced Melanoma: Results of a Dose-Finding Trial

Wen-Jen Hwu, Susan E. Krown, Katherine S. Panageas, Jennifer H. Menell, Paul B. Chapman, Philip O. Livingston, Linda Williams, Carolyn Quinn, Alan N. Houghton

Journal of Clinical Oncology · 2002 · 66 citations · 16 references

DOI

Abstract

The combination of temozolomide and thalidomide was well tolerated and had antitumor activity in patients with advanced melanoma, including elderly patients over 70 years old.

References

16

Thalidomide is an inhibitor of angiogenesis.

Robert J. D’Amato, Michael Loughnan, Evelyn Flynn et al. · Proceedings of the National Academy of Sciences · 1994 · 2.5K citations · Full text

, , +13

Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer.

Timothy M. Browder, Catherine Butterfield, Birgit M. Kräling et al. · PubMed · 2000 · 1.6K citations

, , +14

Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma

Mark R. Middleton, Jean‐Jacques Grob, Neil K. Aaronson et al. · Journal of Clinical Oncology · 2000 · 1.3K citations

Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes.

E P Sampaio, Euzenir Nunes Sarno, Ruth Galilly et al. · The Journal of Experimental Medicine · 1991 · 1.2K citations · Full text

, , +22

Multicenter Phase II Trial of Temozolomide in Patients With Anaplastic Astrocytoma or Anaplastic Oligoastrocytoma at First Relapse

W.K. Alfred Yung, Michael D. Prados, Ricardo Yayá et al. · Journal of Clinical Oncology · 1999 · 757 citations